With close ties to University of Chicago where some of the work on which the firm is based was undertaken and which institution also invested in start up of the firm. With the focus on treatment and prevention of kidney stones, Oxalo is structured to work with a drug that mimics a microbe found in the body that helps to prevent kidney stones by removing oxalate, the toxic molecule that, when combined with calcium, causes most kidney stones. The drug on which Oxalo is working treats primary and secondary hyperoxaluria, and resulting severe recurrent kidney stones. Using the University of Chicago breakthrough microbiome research, the firm directly targets the biology of these diseases and can uniquely utilize the orphan drug pathway in clinical trials.
